Chemo-Hormone combo boosts survival in advanced prostate cancer
Disease control
Completed
This study tested whether adding chemotherapy (docetaxel) to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men with cancer that had spread were randomly assigned to get hormone therapy alone or hormone therapy plus chemo. The main goal was to…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:04 UTC